Treprostinil prodrug transdermal - Corsair Pharma/United Therapeutics

Drug Profile

Treprostinil prodrug transdermal - Corsair Pharma/United Therapeutics

Alternative Names: CO-254; transdermal treprostinil prodrug patch - United Therapeutics; VPD-380

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corsair Pharma
  • Developer United Therapeutics Corporation
  • Class Antihypertensives; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Pulmonary arterial hypertension

Most Recent Events

  • 03 Jan 2018 United Therapeutics in-licenses portfolio of patents covering treprostinil prodrugs from Corsair Pharma
  • 03 Jan 2018 Early research in Pulmonary arterial hypertension in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top